Drug resistance in ovarian cancer: from mechanism to clinical trial

Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical practice poses challenges for the treatment of drug-resistant ovarian cancer. Continuing to classify drug resistance according to drug type without understanding the underlying mechanisms is unsuitable for current clinical practice. We reviewed the literature regarding various drug resistance mechanisms in ovarian cancer and found that the main resistance mechanisms are as follows: abnormalities in transmembrane transport, alterations in DNA damage repair, dysregulation of cancer-associated signaling pathways, and epigenetic…

• NN
  National Natural Science Foundation of China

  Awards: 82073129, No. 82073129
• CS
  Chongqing Science and Technology Commission

  Award: No. CSTB2023NSCQ-MSX1030, No. cstc2022jxjl120039
• CS
  Centre Scientifique et Technique du Bâtiment